LABORATORIO FARMAC.ERFO Net Assets
LABORATORIO FARMAC.ERFO net assets. Based on the latest financial reports, LABORATORIO FARMAC.ERFO (RK7) has net assets worth €7.54 Million EUR (≈ $8.82 Million USD) as of June 2024. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€10.52 Million ≈ $12.30 Million USD) and total liabilities (€2.98 Million ≈ $3.48 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore net asset growth rate of LABORATORIO FARMAC.ERFO to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €7.54 Million |
| % of Total Assets | 71.69% |
| Annual Growth Rate | 29.12% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Net Assets of LABORATORIO FARMAC.ERFO (2021–2023)
Net assets of LABORATORIO FARMAC.ERFO from 2021 to 2023. This chart illustrates how LABORATORIO FARMAC.ERFO's net assets have evolved over time, based on quarterly financial data. See RK7 net asset quality score to measure how much of total assets are equity-financed.
Annual Net Assets for LABORATORIO FARMAC.ERFO (2021–2023)
The table below shows the annual net assets of LABORATORIO FARMAC.ERFO from 2021 to 2023. For live market cap and overall valuation, see RK7 company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | €7.88 Million ≈ $9.21 Million |
-- |
| 2022-12-31 | €0.00 ≈ $0.00 |
-- |
| 2021-12-31 | €4.73 Million ≈ $5.53 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to LABORATORIO FARMAC.ERFO's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 55.5% over the analyzed period, potentially due to dividend distributions or operating losses.
LABORATORIO FARMAC.ERFO Net Assets Breakdown (December 2023)
LABORATORIO FARMAC.ERFO net assets breakdown by equity component as of December 2023.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €515.76K | 6.56% |
| Other Components | €7.34 Million | 93.44% |
| Total Equity | €7.86 Million | 100.00% |
LABORATORIO FARMAC.ERFO Competitors by Market Cap
The table below lists competitors of LABORATORIO FARMAC.ERFO ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Holand og Setskog Sparebank
OL:HSPG
|
$8.69 Million |
|
Jaya Trishindo Tbk PT
JK:HELI
|
$8.69 Million |
|
Akkhie Prakarn Public Company Limited
BK:AKP
|
$8.69 Million |
|
Stamper Oil & Gas Corp
V:STMP
|
$8.69 Million |
|
W.A.G payment solutions plc
LSE:EWG
|
$8.69 Million |
|
Gulf & Pacific Equities Corp
V:GUF
|
$8.67 Million |
|
Duketon Mining Ltd
AU:DKM
|
$8.67 Million |
|
SSH GROUP LTD
F:JRSA
|
$8.66 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in LABORATORIO FARMAC.ERFO's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 3,466,072 to 7,860,292, a change of 4,394,220 (126.8%).
- Net income of 553,815 contributed positively to equity growth.
- Dividend payments of 165,963 reduced retained earnings.
- Share repurchases of 456,556 reduced equity.
- Other factors increased equity by 4,462,924.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €553.82K | +7.05% |
| Dividends Paid | €165.96K | -2.11% |
| Share Repurchases | €456.56K | -5.81% |
| Other Changes | €4.46 Million | +56.78% |
| Total Change | €- | 126.78% |
Book Value vs Market Value Analysis
This analysis compares LABORATORIO FARMAC.ERFO's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.95x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.66x to 0.95x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €0.53 | €0.87 | x |
| 2022-12-31 | €0.39 | €0.87 | x |
| 2023-12-31 | €0.91 | €0.87 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently LABORATORIO FARMAC.ERFO utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.05%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 9.34%
- • Asset Turnover: 0.58x
- • Equity Multiplier: 1.29x
- Recent ROE (7.05%) is below the historical average (17.45%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 24.66% | 24.20% | 0.69x | 1.47x | €693.08K |
| 2022 | 20.66% | 15.17% | 0.45x | 3.04x | €369.46K |
| 2023 | 7.05% | 9.34% | 0.58x | 1.29x | €-232.21K |
Industry Comparison
This section compares LABORATORIO FARMAC.ERFO's net assets metrics with peer companies in the Packaged Foods industry.
Industry Context
- Industry: Packaged Foods
- Average net assets among peers: $77,695,985,483
- Average return on equity (ROE) among peers: -36.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| LABORATORIO FARMAC.ERFO (RK7) | €7.54 Million | 24.66% | 0.39x | $8.69 Million |
| COFCO Joycome Foods Limited (0M7) | $9.59 Billion | 5.61% | 1.12x | $599.97 Million |
| Nomad Foods Limited (0NH) | $2.59 Billion | 7.43% | 1.48x | $1.18 Billion |
| DaChan Food (Asia) Limited (3DS) | $2.27 Billion | 6.85% | 0.52x | $69.71 Million |
| JATCORP LTD. (3J2) | $8.15 Million | -85.51% | 2.68x | $4.79 Million |
| MEIJI HLD.UN.ADR 1/4 O.N. (3M00) | $751.31 Billion | 9.24% | 0.51x | $5.80 Billion |
| PSYCHED WELLNESS LTD (5U9) | $3.10 Million | -162.18% | 0.21x | $475.49K |
| EAT WELL INVESTMENT GROUP (6BC0) | $4.28 Million | -151.49% | 12.09x | $6.16 Million |
| BOOSH PLANT-BASED BRANDS (77I) | $-3.96 Million | 0.00% | 0.00x | $101.47K |
| ELEMENT NUTR.SCIENCES (93X) | $-8.47 Million | 0.00% | 0.00x | $2.06 Million |
| ASSOC. BR. FOODS ADR 1 (AFO2) | $11.19 Billion | 9.33% | 0.68x | $15.67 Billion |
About LABORATORIO FARMAC.ERFO
Laboratorio Farmaceutico Erfo S.p.A. engages in the formulation and production of food supplements in Italy. It produces various types of pharmaceutical forms, such as bottles, single-dose vials and bottles, capsules, tablets, and sachets under the Diètnatural and Gianopharma brands, as well as private label brands. The company offers custom formula creation, regulatory advice, graphics, and pack… Read more